Related Experiment Video

Updated: May 11, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

Metronidazole affects breast cancer cell lines

A Sadowska1, S Prokopiuk, W Miltyk

  • 1Department of Experimental Pharmacology, Medical University of Bialystok, Bialystok, Poland. zfarmdosw@umb.edu.pl

Advances in Medical Sciences
|May 4, 2013
PubMed
Abstract

Insights

Metronidazole (MTZ) shows varied effects on breast cancer cells, impacting estrogen receptor-positive and negative lines differently. These findings suggest estrogen signaling influences MTZ

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Breast cancer exhibits heterogeneity, with estrogen receptor (ER) status significantly influencing treatment response.
  • Metronidazole (MTZ), an antibiotic, has been investigated for potential anticancer properties.

Purpose of the Study:

  • To investigate the differential effects of metronidazole (MTZ) on cytotoxicity and DNA synthesis in ER-positive (MCF-7) and ER-negative (MDA-MB-231) human breast cancer cell lines.

Main Methods:

  • Cytotoxicity was assessed using the MTT assay.
  • Cells were exposed to various MTZ concentrations (0.1-250 μg/ml) for 24, 48, and 72 hours.
  • DNA synthesis was quantified by measuring [3H]-thymidine incorporation.

Main Results:

  • MTZ demonstrated dose- and time-dependent effects.
  • In MCF-7 cells, MTZ (250 μg/ml) increased proliferation at 24h but reduced viability at 72h (1-10 μg/ml).
  • MDA-MB-231 cells showed increased viability with MTZ (250 μg/ml) at 24h and 72h, and suppressed proliferation at lower concentrations (0.1-50 μg/ml) after 72h.
  • Increased [3H]-thymidine incorporation was observed in MCF-7 cells at 250 μg/ml MTZ after 24h.

Conclusions:

  • Metronidazole exhibits distinct dose- and time-dependent effects on human breast cancer cell lines.
  • The observed discrepancies in MTZ's impact on ER-positive versus ER-negative cells suggest a role for estrogen signaling.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers06:02

Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers

Published on: February 20, 2017

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...